ClinicalTrials.gg
CompletedNCT06053424Updated Aug 27, 2025

Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

A Phase 1 interventional study of AZD7798 and [11C]AZ14132516 in Crohn's Disease, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Crohn Disease by AstraZeneca — none open to participants now, 2 under way, none of them phase 3. Crohn Disease · AstraZeneca.

Enrollment
12th of 13
13 · median 48
Started
2023
the only one that year
Phase 1
5 of 13
none open now
Registered
10th of 13
by date

Among the 13 studies in Crohn Disease by AstraZeneca, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 1, and was the 10th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 13 studies in Crohn Disease by AstraZeneca is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Crohn Disease by AstraZeneca as a file.
02

Study summary

The purpose of this study is to measure the changes in small bowel uptake of radioligand [11\^C]AZ14132516 after intravenous (IV) administration of single and repeat doses of AZD7798 in healthy participants and participants with Crohn's disease.

Study details include:

  • The study duration will be variable (adaptive design).
  • For Panels 1-5, there will be 5 in-person study visits: 1 screening visit, 1 visit for the baseline PET examination, 1 residential (24 hour) visit for AZD7798 administration and 2 visits for repeated PET examinations. There will be a final follow-up virtual visit (telephone call).
  • For Panel 6, there will be 7 in-person study visits: 1 screening visit, 1 visit for the baseline PET examination, 2 residential (24 hour) visits for AZD7798 administration, 1 visit for pharmacokinetic (PK) blood sample and 2 visits for repeated PET examinations. There will be a final follow-up virtual visit.
03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

HEALTHY PARTICIPANTS:

  1. Capable of giving signed as described in Appendix A which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
  2. Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.
  3. Participant must be ≥ 20 to 65 years of age inclusive, at the time of signing the informed consent.

    Type of Participant and Disease Characteristics

  4. Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory parameters, and cardiac monitoring before first administration of product.

    Weight

  5. Body weight within 50.0 to 120.0 kg and within the range 18.0 to 35.0 kg/m\^2 (inclusive).
  6. use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male participants:

      • Non-sterilized male participants who are sexually active with a female partner of must use a condom with spermicide during the study period and for at least 7 days following last radioligand administration and 4 months following last dose of AZD7798, whichever is longer.
      • It is strongly recommended that female partners of male participants also use at least one highly effective method of contraception throughout this period.
      • Male participants must refrain from fathering a child or donating sperm during the study period and for at least 7 days following last radioligand administration and 4 months following last dose of AZD7798, whichever is longer.
    2. Female participants:

    (i) Women of non-child bearing potential are defined as meeting one of the following criteria at screening:

    • defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and follicle-stimulating hormone levels in the postmenopausal range.
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.

    (ii) Woman of childbearing potential (WOCBP ie, not meeting criteria above) must have a negative pregnancy test at screening and before PET examination.

    (iii) If sexually active with a non-sterilized male partner, WOCBP must use at least one highly effective method of birth control during the study period and for at least 7 days following last radioligand administration and 4 months following last dose of AZD7798, whichever is longer.

    (iv) It is strongly recommended that non-sterilized male partners of WOCBP participants use a male condom plus spermicide during the study period.

    (v) WOCBP participants must not breastfeed and must not donate or retrieve ova for their own use during the study period and for at least 7 days following last radioligand administration and 4 months following last dose of AZD7798, whichever is longer (c) Highly effective methods of birth control (i) Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include:

    • Combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal)
    • Progesterone-only contraception associated with inhibition of ovulation (oral, injectable or implantable)
    • Intrauterine device or hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomized partner (only acceptable if the partner is the sole sexual partner of the participant and the vasectomized partner has received medical assessment of surgical success)
    • Sexual abstinence as defined by refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. It is only acceptable if the preferred and usual lifestyle of the participant.

    PARTICIPANTS WITH CROHN'S DISEASE

<!-- -->

  1. As for Healthy Participants (inclusion criteria #1) procedures.
  2. Participant must be ≥ 20 to 65 years of age inclusive, at the time of signing the informed consent.
  3. Participants with confirmed Crohn's disease with small bowel involvement per study gastroenterologist (diagnosed via combination of clinical findings and at least one of endoscopy and/or histology and/or imaging) with diagnosis made at least 3 months prior to screening.
  4. Body weight within 50.0 to 120.0 kg and body mass index within the range 18.0 to 35.0 kg/m\^2 (inclusive).
  5. As for Healthy Participants (inclusion criteria #6).

Exclusion criteria

Exclusion Criteria:

HEALTHY PARTICIPANTS:

  1. Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, hematological disease, hepatic disease, renal disease, gastrointestinal disease, or other major disease.
  2. History of cancer with the following exceptions

    (a) Solid with curative therapy completed at least 5 years prior to screening (b) Basal cell carcinoma or localized squamous cell carcinoma of the skin or in-situ carcinoma of the cervix, provided that curative therapy was completed at least 12 months prior to screening

  3. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to biologic therapies.
  4. Participants with unstable hypertension (as judged by the Investigator) or symptomatic hypotension, history of pre-syncope or syncope due to orthostatic hypotension and/or induced by change of posture (orthostatic hypotension defined as 25 mmHg decrease in systolic and/or 15 mmHg).
  5. Significant abnormalities on clinical examination, including neurological and physical examination, vital signs and (ECG).
  6. Chemistry, hematology, or urine analysis results that may interfere with the study or present a safety risk to the participant.
  7. Leukocyte, lymphocyte, or below the lower limit of normal. A re-test is allowed during screening in cases of mild leukopenia clinically suspected to be transient.
  8. Abnormal vital signs, after 10 minutes of supine rest as judged by the investigator. As a guide, any readings outside the following should be considered in the evaluation:

    (a) systolic blood pressure (BP) ≥ 150 mmHg (b) diastolic BP ≥ 90 mmHg (c) heart rate ≤ 35 beats per minute (bpm) or ≥ 100 bpm The inclusion of participants meeting the above criteria may be decided on a case-by case basis by the Principal Investigator (PI).

  9. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of changes. This may include participants with any of the following:

    1. PR (PQ) interval prolongation of clinical significance as judged by the Investigator
    2. Intermittent second or third-degree atrioventricular (AV) block (AV block II Mobitz type 1, Wenchebach, while asleep or in deep rest is not disqualifying)
    3. Incomplete, full, or intermittent bundle branch block (QRS ≤ 110 ms with normal QRS and T wave morphology is acceptable if there is no evidence of left ventricular hypertrophy)
    4. Abnormal T wave morphology
    5. Prolonged QTcF ≥ 470 ms or shortened QTcF ≤ 340 ms or a family history of long QT syndrome The inclusion of participants meeting the above criteria may be decided on a case-by case basis by the PI.
  10. Positive , , or (HIV) serology as defined by:

    (a) Hepatitis B surface antigen (HBsAg) or anti-hepatitis B core antibodies (anti-HBc Ab) positivity (b) Anti-hepatitis C virus antibodies (anti-HCV Ab) positivity (c) Anti-HIV antibodies (Ab) positivity Prior/Concomitant Therapy

  11. Participants must abstain from taking prescription or non-prescription drugs (including vitamins, recreational drugs, and dietary or herbal supplements) within 7 days or 5 half-lives (whichever is longer) before the start of study intervention until completion of the follow-up visit, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.
  12. Current drug abuse or dependence or positive screen for drugs of abuse at screening visit.
  13. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  14. Suffers from claustrophobia that limits the ability to undergo the scanning procedure.
  15. Positive Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapid antigen test at screening.
  16. Any other reason that, in the study PI opinion, prohibits the inclusion of the participants into the study.
  17. Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  18. Live or attenuated vaccine within 4 weeks of Screening and until the end of the follow-up period and until 12 weeks after the end of the follow-up period (1 year for Bacillus Calmette-Guerin [BCG] vaccination).
  19. An active infection, or history of serious infection within the preceding 28 days.
  20. Use of antibiotics within 28 days prior to the first administration of medicinal product (IMP), unless, in the opinion of the investigator, the medication will not interfere with the study.
  21. History of symptomatic herpes simplex (excluding cold sores) or herpes zoster infection within 3 months prior to screening.
  22. Positive or indeterminate tuberculosis (TB) QuantiFERON test.
  23. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days/5 half-lives, whichever is longer, of the first administration of IMP in this study. The period of exclusion begins 30 days/5 half-lives, whichever is longer, after the final dose.
  24. Participation in a PET imaging research study within last year.

PARTICIPANTS WITH CROHN'S DISEASE

  1. Current diagnosis of ulcerative colitis, indeterminate colitis, inflammatory bowel disease unclassified, infectious colitis, or ischemic colitis.
  2. History of cytomegalovirus colitis within 12 months prior to screening.
  3. Complications of Crohn's Disease including short bowel syndrome, strictures/stenoses with symptomatic obstruction or pre-stenotic dilation, or other conditions where surgery may be anticipated during the study period.
  4. Planned bowel or perianal surgery for Crohn's disease prior to end of study follow up visit.
  5. Recent bowel resection surgery within 6 months of screening.
  6. Participants with undrained fistula or abscess, including active perianal disease.
  7. Positive Clostridium difficile toxin test during screening.
  8. Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, hematological disease, hepatic disease, renal disease, gastrointestinal disease, or other major diseases other than active Crohn's disease.
  9. History of cancer with the following exceptions (a) Solid malignancy with curative therapy completed at least 5 years prior to screening (b) Basal cell carcinoma or localized squamous cell carcinoma of the skin or in-situ carcinoma of the cervix, provided that curative therapy was completed at least 12 months prior to screening
  10. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to biologic therapies.
  11. Participants with unstable hypertension (as judged by the Investigator) or symptomatic hypotension, history of pre-syncope or syncope due to orthostatic hypotension and/or induced by change of posture (orthostatic hypotension defined as 25 mmHg decrease in systolic and/or 15 mmHg).
  12. Significant abnormalities on clinical examination, including neurological and physical examination, vital signs and ECG other than signs of Crohn's disease.
  13. Chemistry, hematology, or urine analysis results that may interfere with the study or present a safety risk to the participant.
  14. Abnormal vital signs, after 10 minutes of supine rest as judged by the investigator. As a guide, any readings outside the following should be considered in the evaluation:

    1. systolic BP ≥ 150 mmHg
    2. diastolic BP ≥ 90 mmHg
    3. heart rate ≤ 35 bpm or ≥100 bpm The inclusion of participants meeting the above criteria may be decided on a case-by case basis by the PI.
  15. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. This may include participants with any of the following:

    1. PR (PQ) interval prolongation of clinical significance as judged by the Investigator
    2. Intermittent second or third-degree AV block (AV block II Mobitz type 1, Wenchebach, while asleep or in deep rest is not disqualifying)
    3. Incomplete, full, or intermittent bundle branch block (QRS ≤ 110 ms with normal QRS and T wave morphology is acceptable if there is no evidence of left ventricular hypertrophy)
    4. Abnormal T wave morphology
    5. Prolonged QTcF ≥ 470 ms or shortened QTcF ≤ 340 ms or a family history of long QT syndrome.

    The inclusion of participants meeting the above criteria may be decided on a case-by case basis by the PI.

  16. Positive hepatitis B, hepatitis C or HIV serology as defined by:

    1. HBsAg or anti-HBc Ab positivity
    2. Anti-HCV Ab positivity and HCV RNA positivity
    3. Anti-HIV Ab positivity Prior/Concomitant Therapy
  17. Treatment with an anti-tumor necrosis factor (anti-TNF) biologic within 8 weeks of first dose and throughout the study period, unless therapeutic drug monitoring is performed and drug concentrations are undetectable.
  18. Treatment with any biologic, other than an anti-TNF (including vedolizumab and ustekinumab) within 12 weeks prior to first dose and throughout the study period, unless therapeutic drug monitoring is performed and drug concentrations are undetectable.
  19. Treatment with rituximab within 12 months prior to first dose and throughout the study period.
  20. Treatment with Sphingosine-1-phosphate receptor modulators within 12 weeks prior to first dose and throughout the study period.
  21. Treatment with Janus Kinase inhibitors within 2 weeks prior to first dose and throughout the study period
  22. Treatment with apheresis (eg, Adacolumn, Cellsorba) within 2 weeks prior to first dose and throughout the study period.
  23. Treatment with at a total daily dose of greater than 20 mg prednisone or equivalent.
  24. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  25. Suffers from claustrophobia that limits the ability to undergo the scanning procedure.
  26. Positive SARS-CoV-2 rapid antigen test at screening.
  27. Any other reason that, in the study PI opinion, prohibits the inclusion of the participants into the study.
  28. Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  29. Live or attenuated vaccine within 4 weeks of screening and until 12 weeks after the end of the follow-up period (1 year for BCG vaccination).
  30. An active infection, or history of serious infection within the preceding 28 days.
  31. History of symptomatic herpes simplex (excluding cold sores) or herpes zoster infection within 3 months prior to screening.
  32. Positive or indeterminate TB QuantiFERON test performed within 1 year of screening (without known interval exposure to TB) or during screening period unless evidence of completion of full treatment course for latent TB with no clinical symptoms or signs indicative of re-activation.
  33. Chest x-ray with signs of malignancy or latent or active TB infection performed within 1 year of screening (without known interval exposure to TB) or during screening period.
  34. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days/5 half-lives, whichever is longer, of the first administration of IMP in this study. The period of exclusion begins 30 days/5 half-lives, whichever is longer, after the final dose.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Panel 1

    Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 1 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42.

    Drug: AZD7798 · Drug: [11C]AZ14132516

  • Experimental
    Panel 2

    Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 56.

    Drug: AZD7798 · Drug: [11C]AZ14132516

  • Experimental
    Panel 3

    Healthy participants will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 2 and Day 42.

    Drug: AZD7798 · Drug: [11C]AZ14132516

  • Experimental
    Panel 4

    Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 1 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42.

    Drug: AZD7798 · Drug: [11C]AZ14132516

  • Experimental
    Panel 5

    Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by a single IV infusion of AZD7798 Dose Level 2 on Day 1. Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 42.

    Drug: AZD7798 · Drug: [11C]AZ14132516

  • Experimental
    Panel 6

    Participants with Crohn's disease will receive a single IV bolus dose of radioligand \[11\^C\]AZ14132516 between Day -7 to Day -1 followed by IV infusion of AZD7798 Dose Level 1 on Day 1 (Dose 1) and Day 15 (Dose 2). Thereafter, again will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 on Day 14 and Day 28.

    Drug: AZD7798 · Drug: [11C]AZ14132516

Interventions

  • Participants will receive IV infusion of AZD7798 as stated in arm description.

  • Drug[11C]AZ14132516

    Participants will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 as stated in arm description.

06

What researchers measure

Primary outcomes

  1. Percentage Change in Small Bowel Partition Coefficient (Kp) From Baseline (Positron Emission Tomography [PET]1 Visit) to PET2 Visit

    Kp is the partition coefficient that denotes radioactivity concentration ratio (area under the concentration-time curve \[AUC\] 0-60 min, intestines/AUC 0-60 min, blood). Kp denotes that denominator is the radioactivity measurement in blood (aorta), this is the reference region used in calculations. Percentage change in small bowel Kp from baseline (PET1 Visit) to PET2 visit is reported.

    Time frame: PET1 visit (baseline; Day -7 to Day -1) and PET2 visit (Day 14 for all panels except Day 2 for Panel 3)

  2. Percentage Change in Small Bowel Kp From Baseline (PET1 Visit) to PET3 Visit

    Kp is the partition coefficient that denotes radioactivity concentration ratio (area under the concentration-time curve \[AUC\] 0-60 min, intestines/AUC 0-60 min, blood). Kp denotes that denominator is the radioactivity measurement in blood (aorta), this is the reference region used in calculations. Percentage change in small bowel Kp from baseline (PET1 Visit) to PET3 visit is reported.

    Time frame: PET1 visit (baseline; Day -7 to Day -1) and PET3 visit (Day 42 for all panels except Days 56 and 28 for Panels 2 and 6, respectively)

Secondary outcomes

  1. Percentage Change From Baseline in Circulating C-C Chemokine Receptor Type 9 Positive (CCR9+) Memory T Cells in Panels 1 to 5

    CCR9+ memory T cells in blood were evaluated by flow cytometry. Percentage change from baseline in circulating CCR9+ memory T cells is reported.

    Time frame: Panels 1-5: Pre-dose (baseline) and 6 and 24 hours post-dose on Day 1, additionally; Panels 1, 4, and 5: Days 14 and 42; Panel 2: Day 14; Panel 3: Days 2 and 42

  2. Percentage Change From Baseline in Circulating CCR9+ Memory T Cells in Panel 6

    CCR9+ memory T cells in blood were evaluated by flow cytometry. Percentage change from baseline in circulating CCR9+ memory T cells is reported.

    Time frame: Pre-dose of Dose 1 (baseline), and 6 and 24 hours post-dose 1 on Day 1; pre-dose and 24 hours post-dose 2 on Day 15; and on Day 28

  3. Change From Baseline in C-C Chemokine Receptor Type 9 (CCR9) Receptor Occupancy as Free CCR9 on Total CCR9 Memory T cells in Blood in Panels 1 to 5

    CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood was evaluated by flow cytometry. Change from baseline in CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood is reported.

    Time frame: Panels 1-5: Pre-dose (baseline) and 6 and 24 hours post-dose on Day 1, additionally; Panels 1, 4, and 5: Days 14 and 42; Panel 2: Day 14; Panel 3: Days 2 and 42

  4. Change From Baseline in CCR9 Receptor Occupancy as Free CCR9 on Total CCR9 Memory T cells in Blood in Panel 6

    CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood was evaluated by flow cytometry. Change from baseline in CCR9 receptor occupancy as free CCR9 on total CCR9 memory T cells in blood is reported.

    Time frame: Pre-dose of Dose 1 (baseline), and 6 and 24 hours post-dose 1 on Day 1; pre-dose and 24 hours post-dose 2 on Day 15; and on Day 28

  5. Serum Concentrations of AZD7798 in Panels 1 to 5

    Serum concentrations of AZD7798 collected over time are reported.

    Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2

  6. Serum Concentrations of AZD7798 in Panel 6

    Serum concentration of AZD7798 collected over time are reported.

    Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29

  7. Maximum Serum Concentration (Cmax) of AZD7798 in Panels 1 to 5

    The Cmax of AZD7798 is reported.

    Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2

  8. Cmax of AZD7798 in Panel 6

    The Cmax of AZD7798 is reported.

    Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29

  9. Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Measured Concentration (AUClast) of AZD7798 in Panels 1 to 5

    The AUClast of AZD7798 is reported.

    Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2

  10. AUClast of AZD7798 in Panel 6

    The AUClast of AZD7798 is reported.

    Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29

  11. Time to Maximum Serum Concentration (Tmax) of AZD7798 in Panels 1 to 5

    The Tmax of AZD7798 is reported.

    Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2

  12. Tmax of AZD7798 in Panel 6

    The Tmax of AZD7798 is reported.

    Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29

  13. Last Measured Serum Concentration (Tlast) of AZD7798 in Panels 1 to 5

    The Tlast of AZD7798 is reported.

    Time frame: Panels 1-5: Pre-dose, 1, 6, 24 hours post-dose on Day 1; additionally, Panels 1, 2, 4, and 5: Day 14; Panel 3: Day 2

  14. Tlast of AZD779 in Panel 6

    The Tlast of AZD7798 is reported.

    Time frame: Pre-dose, 1, 6, and 24 hours post-dose 1 on Day 1; pre-dose, 1, 6, and 24 hours post-dose 2 on Day 15; and on Day 29

  15. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day -7 to Day -1 through Day 49 for all panels except Panel 2 (Day -7 to Day -1 through Day 63) and Panel 6 (Day -7 to Day -1 through Day 35)

  16. Number of Participants With Abnormal Vital Signs Reported as TEAEs

    Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, pulse rate, and oxygen saturation).

    Time frame: Day -7 to Day -1 through Day 49 for all panels except Panel 2 (Day -7 to Day -1 through Day 63) and Panel 6 (Day -7 to Day -1 through Day 35)

  17. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

    Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of clinical chemistry, hematology, coagulation, urinalysis, and drug abuse (healthy participants only).

    Time frame: Day -7 to Day -1 through Day 49 for all panels except Panel 2 (Day -7 to Day -1 through Day 63) and Panel 6 (Day -7 to Day -1 through Day 35)

07

Study locations

1 site
  • Research Site
    Stockholm, 14186, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Oct 2024, 12 months.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 25, 2023
StartActual
Sep 25, 2023
Primary completionActual
Oct 8, 2024
CompletionActual
Oct 8, 2024
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06053424
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Sep 25, 2023
Primary completion
Oct 8, 2024
Completion
Oct 8, 2024
Last update
Aug 27, 2025

Study contacts

Maria Creignou, MD
principal investigator · Karolinska University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD7798

Start the discussion